Supraventricular Tachycardia | Dexmedetomidine and Adenosine: Therapeutic Use for SVT

Supraventricular Tachycardia research study

What is the primary objective of this study?

The purpose of this study is to evaluate the efficacy and safety of dexmedetomidine in the acute termination of Supraventricular Tachycardia (SVT).

Who is eligible to participate?

Inclusion Criteria: - Patients between the age of 5 - 30 years old, who are scheduled for cardiac electrophysiology study for evaluation of reentrant SVT Exclusion Criteria: - Severe Heart Failure - Presence of of any other antiarrhythmic medication within 24 hours of enrollment - Third degree heart block - Sick Sinus Syndrome

Which medical condition, disease, disorder, syndrome, illness, or injury is researched?

Supraventricular Tachycardia

Study Interventions

Interventions can include giving participants drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available or noninvasive approaches such as surveys, education, and interviews.

Drug:DexmedetomidineDexmedetomidine 2 mcg/kg, Intravenous push

Drug:AdenosineStepwise incremental approach of adenosine starting at 0.2 mg/kg (max 6 mg) followed by 0.3 mg/kg (max 12 mg) if initial dose was unsuccessful

Study Arms

Research studies and clinical trials typically have two or more research arms. An arm is a group of people who receive the same treatment in the study.

Adenosine and DexmedetomidinePatients will receive adenosine and then dexmedetomidine for the termination of SVT

Study Status


Start Date: January 2012

Completed Date: July 2014

Phase: N/A

Type: Interventional


Primary Outcome: Termination of SVT

Secondary Outcome: Number of Participants With Sinus Pause >2.5 Sec After Termination of SVT

Study sponsors, principal investigator, and references

Principal Investigator: Gaurav Arora, MD

Lead Sponsor: University of Pittsburgh


More information:

Chrysostomou C, Beerman L, Shiderly D, Berry D, Morell VO, Munoz R. Dexmedetomidine: a novel drug for the treatment of atrial and junctional tachyarrhythmias during the perioperative period for congenital cardiac surgery: a preliminary study. Anesth Analg. 2008 Nov;107(5):1514-22. doi: 10.1213/ane.0b013e318186499c.

Discuss Tachycardia